24/7 Market News Snapshot 01 August, 2025 – Kazia Therapeutics Limited American Depositary Shares (NASDAQ:KZIA)

August 1, 2025

DENVER, Colo., 01 August, 2025 (www.247marketnews.com) – (NASDAQ:KZIA) are discussed in this article.
Kazia Therapeutics Limited (NASDAQ:KZIA) has demonstrated a robust upward trajectory in its stock performance, currently trading at $8.755, marking a 4.47% increase from the previous close of $8.380. This positive movement is supported by a strong trading volume of 654.88K shares, indicating significant investor interest. Market analysts are observing this momentum closely, as traders anticipate resistance levels around $9.00 and maintain bullish positions in light of the favorable sentiment surrounding the stock.

In a strategic move to bolster its oncology drug development initiatives, Kazia has announced a significant capital initiative involving a securities purchase agreement with a select group of institutional investors. This initiative is projected to raise approximately $2 million through a private placement of equity securities, to be issued at a 5% premium above the closing price of Kazia’s American Depositary Shares as of July 31, 2025. The expected close date for this transaction is August 4, 2025, pending customary conditions and regulatory compliance.

The capital raised through this initiative is earmarked for the continued clinical development of Kazia’s lead drug programs, including paxalisib, a dual PI3K/mTOR inhibitor currently in trials for brain cancer and advanced breast cancer, as well as EVT801, a selective VEGFR3 inhibitor in Phase 1 clinical trials. Dr. John Friend, CEO of Kazia Therapeutics, expressed optimism regarding the funding, highlighting its role in advancing the company’s clinical-stage assets through critical upcoming milestones, particularly additional data from the ongoing advanced breast cancer trial.

Kazia’s commitment to innovation in oncology is evident as it prepares to file a registration statement with the U.S. Securities and Exchange Commission (SEC) for the resale of the securities, reflecting its dedication to transparency and growth in the sector. The company remains focused on delivering impactful solutions for cancer patients and anticipates sharing further updates on its clinical progress in the near future.

Related news for (KZIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.